Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Rheumatoid arthritis (RA) patients refractory to one or more TNF-α inhibitors are generally prescribed a non-TNF-targeted therapy (e.g., Bristol-Myers Squibb’s Orencia, Roche’s Actemra / RoActemra, Roche’s Rituxan / MabThera). The recent launch of Pfizer’s Xeljanz in Europe and Eli Lilly / Incyte’s Olumiant in both the United States and Europe provides physicians additional treatment options with a convenient oral route of administration. The launch of an additional IL-6 inhibitor, Regeneron / Sanofi’s Kevzara, has further expanded the treatment armamentarium. Although the RA market offers multiple efficacious and relatively safe agents, patients refractory to TNF-α inhibitors have limited options, even with the recent entry of these newer agents; therefore, unmet need still exists for the TNFi-refractory RA subpopulation.
Unmet Need provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 31 European rheumatologists fielded in February 2019
Key companies: Bristol-Myers Squibb, Roche, Pfizer, Eli Lilly, Incyte, Regeneron, Sanofi
Key drugs: Rituxan / MabThera, Orencia, Actemra / RoActemra, Xeljanz, Olumiant, Kevzara
Already a Client? Log in to access this report.
Qinghui Yu is a business insights analyst at Decision Resources Group. She has authored market research reports analyzing market trends in autoimmune diseases. Prior to joining Decision Resources Group, Dr. Yu worked as a senior analyst for a life science consulting firm, where she worked on a range of projects providing strategic growth advice to clients in life science ;Qinghui Yu holds a in Neuroscience from Columbia University.